{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Statistical Methods (Continued):', 'The hypothesis in H02 will be tested if the hypothesis in Hoib is rejected. If the hypothesis in H02 is', 'rejected, then, either (i) H03 and H04 will be tested sequentially if the PFS endpoint in DLL3high subjects', '(H01a) is also rejected or (ii) only H04 will be tested if the PFS endpoint in DLL3hig subjects (Ho1a) is not', 'rejected.', 'Futility Analysis:', 'Unblinded interim data will be analyzed and reviewed by the IDMC. A futility analysis will be', 'conducted when approximately 160 deaths in subjects with DLL3\u00b9 high ED SCLC (approximately 50% of', 'the planned deaths) are observed. The trial may be stopped for futility if the estimated Overall Survival', 'Cox HR of Rova-T to Placebo at this analysis exceeds 0.9. The one-sided alpha of 10-6 will be spent for', 'the early look at the efficacy data for futility analysis.', 'Sample Size:', 'There are two primary efficacy endpoints for this study: Progression-free survival (PFS) based on the', 'CRAC and overall survival (OS) in subjects with DLL3 high ED SCLC. To maintain the overall 1-sided', 'type I error at a 2.5% for this study, the type I error will be split, assigning 0.25% to progression-free', 'survival and the remaining 2.25% to overall survival. However, the OS endpoint will be tested at a', 'one-sided 2.2499% significance level as a one-sided alpha of 10-6 will be spent for the early look at the', 'OS data for futility analysis.', 'The sample size of the study is primarily determined by the analysis of OS. It is assumed, taking into', 'account the expected patient population for the study, that median overall survival in the placebo and', 'rovalpituzumab tesirine arm will be around 9 months and 13 months, respectively. The increase of', 'median OS in rovalpituzumab tesirine arm corresponds to a hazard ratio of 0.69, i.e., a reduction in the', 'hazard of death by 31%. With all these assumptions, a total of 319 deaths among subjects with DLL3 high', 'are needed to achieve a 90% power based on a log-rank test at a one-sided significance level of 0.022499.', 'Assuming a 19-month accrual period and the last enrolled subject followed for 12 months, at least', '480 subjects with DLL3hig are expected to be randomized (240 subjects in each arm). A total of', '740 subjects regardless of DLL3 expression level (including 480 subjects with DLL36 high will enroll in', 'the study, assuming an approximate prevalence of 65% for subjects with DLL3high For one-sided', 'significance level of 0.022499, it is projected that an observed hazard ratio of 0.799 or less,', 'corresponding to a 2.3 months or greater improvement in median OS, would result in a statistically', 'significant improvement in the primary analysis of OS.', 'The', 'primary endpoints of OS and PFS in DLL3high patients will be analyzed at the same time after', 'observing at-least 319 OS event. It is expected at approximately 420 PFS events will be observed at the', 'time of the primary analysis.', 'It is assumed, taking into account the expected patient population for the study, that median progression-', 'free survival for the placebo and rovalpituzumab tesirine arm will be approximately 3 months and', '4.5 months, respectively. The increase of median progression-free survival in rovalpituzumab tesirine', 'arm corresponds to a hazard ratio of 0.667. With all these assumptions, a total of 420 PFS events', 'assessed by the CRAC for the subjects with DLL3high are needed to achieve a 91% power based on a log-', 'rank test at a one-sided significance level of 0.0025. It is projected that an observed hazard ratio of 0.760', 'or less, corresponding to approximately 1 month or greater improvement in median PFS, would result in', 'a statistically significant improvement in the PFS.', '15']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Statistical Methods (Continued):', 'Pharmacokinetic:', 'Individual concentrations of rovalpituzumab tesirine ADC will be tabulated and summarized for subjects', 'treated with the active regimen and summary statistics provided. The incidence of ATA will be', 'summarized.', 'Biomarkers:', 'Biomarkers will be measured at baseline and post-treatment and analyses performed to identify markers', 'associated with rovalpituzumab tesirine response, pharmacodynamics, PK, or safety.', 'Safety:', 'The safety of rovalpituzumab tesirine will be assessed by evaluating the study drug exposure, adverse', 'events, all deaths, as well as changes in laboratory determinations and vital sign parameters.', '16']\n\n###\n\n", "completion": "END"}